BRNS Barinthus Biotherapeutics plc Forecast, Technical & Fundamental Analysis
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases... Show more
BRNS is expected to report earnings to rise 100.00% to -28 cents per share on August 06
Q2'26
Est.
$-0.28
Q1'26
Beat
by $0.18
Q4'25
Beat
by $0.11
Q3'25
Beat
by $0.04
Q2'25
Missed
by $0.16
The last earnings report on May 01 showed earnings per share of -14 cents, beating the estimate of -31 cents. With 62.11K shares outstanding, the current market capitalization sits at 24.92M.
A.I.dvisor indicates that over the last year, BRNS has been loosely correlated with NGNE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BRNS jumps, then NGNE could also see price increases.
Momentum Indicator for BRNS turns negative, indicating new downward trend
BRNS saw its Momentum Indicator move below the 0 level on June 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 109 similar instances where the indicator turned negative. In of the 109 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for BRNS turned negative on June 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
BRNS moved below its 50-day moving average on June 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BRNS crossed bearishly below the 50-day moving average on July 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 21 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRNS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 71 cases where BRNS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BRNS advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .
BRNS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 67 cases where BRNS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BRNS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.375) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). BRNS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (2.165) is also within normal values, averaging (434.181).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
